|Eligible Active Ingredient:||Nasal Triamcinolone. As an intranasal spray containing not more than 55 mcg/actuation|
|With Effective From:||1-Jul-2012|
|Indication Permitted:||Prevention and treatment of allergic rhinitis|
|Maximum Daily Dose:||220 mcg|
|Maximum Supply per Transaction:||Up to 3 months’ duration.|
|Minimum Age of User:||18 years|
|Patient Information Leaflet from HSA/PSS:||Download PIL (Link to HSA website)|
Mechanism of Action of Nasal Triamcinolone
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Additional Information of Nasal Triamcinolone
|Pharmacology Class:||Decongestants And Other Nasal Preparations For Topical Use|
|Therapeutic Class:||Nasal Preparations|
|Synonyms:||11Œ≤,16Œ±,17Œ±,21-tetrahydroxy-9Œ±-fluoro-1,4-pregnadiene-3,20-dione | 9-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-11Œ≤,16Œ±,17Œ±,21-tetrahydroxypregna-1,4-diene-3,20-dione | 9Œ±-fluoro-16Œ±-hydroxyprednisolone | Fluoxyprednisolone | Tiamcinolonum | Triamcinolona | Triamcinolonum|
Show All HSA-registered therapeutic products granted exemption to supply without prescription
HSA-Registered Products Containing Nasal Triamcinolone As an intranasal spray containing not more than 55 mcg/actuationwpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.